{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003929","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.003576+00:00","generated_at":"2026-06-07T02:22:19.652478+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Crinetics outlines 2024 milestones: paltusotine Phase 3 data Q1, CRN04894 data Q2","bullets":["Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly on track for topline data in Q1 2024.","Phase 2 trial of paltusotine in carcinoid syndrome topline data expected H1 2024; Phase 3 start H2 2024.","Phase 2 trials of CRN04894 (ACTH antagonist) in CAH and Cushing's disease initial data expected Q2 2024.","Preclinical evaluation ongoing for oral small molecules in hyperparathyroidism, PKD, Graves', TED, diabetes, and obesity.","CEO to present at J.P. Morgan Healthcare Conference on Jan 9, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003929","json":"https://secwatch.observer/filing/0001193125-24-003929.json","markdown":"https://secwatch.observer/filing/0001193125-24-003929.md","text":"https://secwatch.observer/filing/0001193125-24-003929.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524003929/0001193125-24-003929-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312524003929/d706423d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:22:19.652478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}